Lantheus (LNTH) Competitors

$76.02
+0.12 (+0.16%)
(As of 05/10/2024 ET)

LNTH vs. RIOT, QDEL, NEOG, CLDX, NTLA, MYGN, OPCH, OGN, BLCO, and HALO

Should you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include Riot Platforms (RIOT), QuidelOrtho (QDEL), Neogen (NEOG), Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Option Care Health (OPCH), Organon & Co. (OGN), Bausch + Lomb (BLCO), and Halozyme Therapeutics (HALO).

Lantheus vs.

Lantheus (NASDAQ:LNTH) and Riot Platforms (NASDAQ:RIOT) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership, media sentiment and community ranking.

99.1% of Lantheus shares are held by institutional investors. Comparatively, 40.3% of Riot Platforms shares are held by institutional investors. 1.5% of Lantheus shares are held by company insiders. Comparatively, 4.4% of Riot Platforms shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Riot Platforms has a net margin of 76.02% compared to Lantheus' net margin of 33.72%. Lantheus' return on equity of 54.10% beat Riot Platforms' return on equity.

Company Net Margins Return on Equity Return on Assets
Lantheus33.72% 54.10% 25.70%
Riot Platforms 76.02%12.56%11.66%

Lantheus has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, Riot Platforms has a beta of 4.19, indicating that its share price is 319% more volatile than the S&P 500.

Riot Platforms received 169 more outperform votes than Lantheus when rated by MarketBeat users. Likewise, 67.34% of users gave Riot Platforms an outperform vote while only 65.21% of users gave Lantheus an outperform vote.

CompanyUnderperformOutperform
LantheusOutperform Votes
328
65.21%
Underperform Votes
175
34.79%
Riot PlatformsOutperform Votes
497
67.34%
Underperform Votes
241
32.66%

Lantheus presently has a consensus price target of $99.17, indicating a potential upside of 30.45%. Riot Platforms has a consensus price target of $18.33, indicating a potential upside of 99.21%. Given Riot Platforms' stronger consensus rating and higher probable upside, analysts clearly believe Riot Platforms is more favorable than Lantheus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lantheus
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86
Riot Platforms
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
3.00

Lantheus has higher revenue and earnings than Riot Platforms. Riot Platforms is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lantheus$1.30B4.06$326.66M$6.5511.61
Riot Platforms$280.70M9.47-$49.47M$0.8710.57

In the previous week, Riot Platforms had 4 more articles in the media than Lantheus. MarketBeat recorded 14 mentions for Riot Platforms and 10 mentions for Lantheus. Lantheus' average media sentiment score of 0.60 beat Riot Platforms' score of 0.16 indicating that Lantheus is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lantheus
3 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Riot Platforms
4 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Riot Platforms beats Lantheus on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LNTH vs. The Competition

MetricLantheusDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$5.27B$2.76B$5.08B$7.79B
Dividend YieldN/A0.75%37.56%3.91%
P/E Ratio11.61143.77160.8517.07
Price / Sales4.0694.152,423.5476.00
Price / Cash11.2516.1947.8335.71
Price / Book5.573.685.314.38
Net Income$326.66M$30.88M$106.14M$217.54M
7 Day Performance0.65%3.06%-0.88%-0.14%
1 Month Performance23.61%-0.33%-3.03%-1.62%
1 Year Performance-23.51%-24.18%4.22%8.90%

Lantheus Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RIOT
Riot Platforms
3.6562 of 5 stars
$10.17
-5.6%
$18.33
+80.2%
-25.1%$2.94B$280.70M11.69534Short Interest ↑
Analyst Revision
QDEL
QuidelOrtho
4.8747 of 5 stars
$43.88
+1.1%
$61.60
+40.4%
-51.1%$2.93B$3.00B-274.257,100Analyst Forecast
NEOG
Neogen
2.7525 of 5 stars
$12.41
+2.2%
$22.50
+81.3%
-28.1%$2.69B$822.45M1,242.242,640
CLDX
Celldex Therapeutics
0.9398 of 5 stars
$42.21
+1.3%
$66.00
+56.4%
+18.9%$2.36B$6.88M-14.51160Analyst Forecast
Analyst Revision
News Coverage
NTLA
Intellia Therapeutics
4.2979 of 5 stars
$23.88
+0.7%
$67.00
+180.6%
-45.9%$2.30B$36.28M-4.41526Analyst Forecast
News Coverage
MYGN
Myriad Genetics
1.8918 of 5 stars
$19.78
-1.0%
$23.17
+17.1%
+43.3%$1.79B$753.20M-6.182,700Earnings Report
Analyst Upgrade
News Coverage
OPCH
Option Care Health
4.9314 of 5 stars
$30.32
+1.0%
$40.00
+31.9%
+11.6%$5.27B$4.30B19.957,802Positive News
OGN
Organon & Co.
4.7957 of 5 stars
$20.40
-1.4%
$22.60
+10.8%
-5.0%$5.25B$6.26B4.9910,000
BLCO
Bausch + Lomb
3.5533 of 5 stars
$14.90
+3.2%
$19.45
+30.6%
-16.0%$5.24B$4.15B-15.5213,300Gap Up
HALO
Halozyme Therapeutics
4.57 of 5 stars
$41.21
+0.9%
$53.29
+29.3%
+25.1%$5.24B$829.25M19.53373Analyst Forecast

Related Companies and Tools

This page (NASDAQ:LNTH) was last updated on 5/11/2024 by MarketBeat.com Staff

From Our Partners